facebook

For adults and children with hemophilia A

REACH HIGHER With the Long-lasting
Protection of AFSTYLA

AFSTYLA, with a twice-weekly dosing option, delivers long-lasting bleed protection using a novel single-chain Factor VIII design

2 times weekly

Twice-weekly dosing can mean fewer infusions each week. Ask your doctor if twice-weekly dosing is right for you.

Twice-weekly dosing

FDA approved for 2 to 3 times
a week.

Learn about AFSTYLA dosing

Zero bleeds  (median AsBR*)

ZERO median annualized spontaneous bleeds* were reported in clinical trials for children and adults regardless of dosing schedule.

ZERO bleeds (median AsBR*)

Regardless of age and dosing schedule.

Explore AFSTYLA protection

*AsBR= annualized spontaneous bleeding rate.

Compared to dosing 3 times a week.

Factor VIII

The safety of AFSTYLA was shown in 258 previously treated children, adolescents, and adults over 19,545 exposure days.

Largest hemophilia A clinical trial program

Zero inhibitors in clinical trials with previously treated people.

See AFSTYLA safety profile

*AsBR=annualized spontaneous bleeding rate.†Compared to dosing 3 times a week.

Get your free AFSTYLA Discovery Kit

Sign up today

Email address

Switching to AFSTYLA is as easy as 1-2-3

Thinking about switching to AFSTYLA from another Factor VIII product?

CSL Behring makes it easy to start on AFSTYLA with a simple 3-step process. You’ll also have access to comprehensive support services that can make a meaningful difference in the lives of people with bleeding disorders.

You can also call 1-800-676-4266 to get detailed information about the services available to you.

See how to switch

CSL Behring an established leader
in bleeding disorders

After more than 30 YEARS of experience in bleeding disorders, CSL Behring remains committed to developing innovative therapies for the people who need them

You are now leaving the current website.

Do you want to continue?

No Yes